JP7141333B2 - 抗－ａｎｇｐｔｌ８抗体及びその使用 - Google Patents

抗－ａｎｇｐｔｌ８抗体及びその使用 Download PDF

Info

Publication number
JP7141333B2
JP7141333B2 JP2018506347A JP2018506347A JP7141333B2 JP 7141333 B2 JP7141333 B2 JP 7141333B2 JP 2018506347 A JP2018506347 A JP 2018506347A JP 2018506347 A JP2018506347 A JP 2018506347A JP 7141333 B2 JP7141333 B2 JP 7141333B2
Authority
JP
Japan
Prior art keywords
antibody
angptl8
antibodies
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018506347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525383A5 (OSRAM
JP2018525383A (ja
Inventor
ヴィクトリア・グサロヴァ
ジェスパー・グロマーダ
アンドリュー・ジェイ・マーフィー
デーヴィッド・アール・バックラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2018525383A publication Critical patent/JP2018525383A/ja
Publication of JP2018525383A5 publication Critical patent/JP2018525383A5/ja
Application granted granted Critical
Publication of JP7141333B2 publication Critical patent/JP7141333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018506347A 2015-08-07 2016-08-04 抗－ａｎｇｐｔｌ８抗体及びその使用 Active JP7141333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202366P 2015-08-07 2015-08-07
US62/202,366 2015-08-07
PCT/US2016/045535 WO2017027316A1 (en) 2015-08-07 2016-08-04 Anti-angptl8 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021034006A Division JP2021090449A (ja) 2015-08-07 2021-03-04 抗−ａｎｇｐｔｌ８抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2018525383A JP2018525383A (ja) 2018-09-06
JP2018525383A5 JP2018525383A5 (OSRAM) 2019-09-05
JP7141333B2 true JP7141333B2 (ja) 2022-09-22

Family

ID=56979626

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018506347A Active JP7141333B2 (ja) 2015-08-07 2016-08-04 抗－ａｎｇｐｔｌ８抗体及びその使用
JP2021034006A Pending JP2021090449A (ja) 2015-08-07 2021-03-04 抗−ａｎｇｐｔｌ８抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021034006A Pending JP2021090449A (ja) 2015-08-07 2021-03-04 抗−ａｎｇｐｔｌ８抗体及びその使用

Country Status (16)

Country Link
US (1) US10259870B2 (OSRAM)
EP (1) EP3331908B1 (OSRAM)
JP (2) JP7141333B2 (OSRAM)
KR (1) KR20180038020A (OSRAM)
CN (1) CN107922478A (OSRAM)
AR (1) AR105600A1 (OSRAM)
AU (1) AU2016307430B2 (OSRAM)
CA (1) CA2993976A1 (OSRAM)
EA (1) EA035088B1 (OSRAM)
ES (1) ES2870031T3 (OSRAM)
HK (1) HK1250238A1 (OSRAM)
IL (1) IL257263A (OSRAM)
MX (1) MX394103B (OSRAM)
TW (1) TW201713690A (OSRAM)
WO (1) WO2017027316A1 (OSRAM)
ZA (1) ZA201800352B (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP3822287A1 (en) 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
HRP20230992T1 (hr) * 2016-02-17 2023-12-08 Regeneron Pharmaceuticals, Inc. Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
PL3439689T3 (pl) * 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
MX382035B (es) * 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
JP6853716B2 (ja) * 2017-03-31 2021-03-31 信越化学工業株式会社 レジスト下層膜材料、パターン形成方法、及びレジスト下層膜形成方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3749691A4 (en) * 2017-11-10 2021-10-27 NGM Biopharmaceuticals, Inc. ANGPTL8 LIAISON AGENTS AND THEIR METHODS OF USE
WO2019126194A1 (en) * 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
PH12022550141A1 (en) 2019-07-19 2023-12-04 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof
CN110613847B (zh) * 2019-10-23 2022-02-11 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN111135303A (zh) * 2020-01-17 2020-05-12 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12391762B2 (en) 2020-08-26 2025-08-19 Twist Bioscience Corporation Methods and compositions relating to GLP1R variants
US20250188154A1 (en) * 2020-09-15 2025-06-12 Duke University Coronavirus antibodies and uses thereof
TWI833641B (zh) * 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
EP4594747A1 (en) * 2022-09-30 2025-08-06 9163-0384 Québec Inc Methods for the assessment of lipoprotein lipase deficiency and lipoprotein lipase bioavailability
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
CN119684452B (zh) * 2024-12-25 2026-03-27 中国药科大学 Angptl8中和性抗体在制备治疗细胞因子风暴综合征药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516518A (ja) 2011-04-25 2014-07-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 共通の軽鎖を有する抗体を発現する非ヒト動物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US6956108B2 (en) 1997-06-16 2005-10-18 Genentech, Inc. PRO1184 antibodies
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
KR20100017169A (ko) 2007-05-22 2010-02-16 노파르티스 아게 Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CN104039357A (zh) * 2011-06-10 2014-09-10 哈佛学院校长同事会 胰腺β-细胞增殖的调节
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
EP2804603A1 (en) * 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US20140178988A1 (en) * 2012-10-08 2014-06-26 Biotime, Inc. Differentiated Progeny of Clonal Progenitor Cell Lines
WO2014183207A1 (en) * 2013-05-17 2014-11-20 Exerkine Corporation Therapeutic method of treating metabolic syndrome
CN104164451A (zh) * 2014-08-09 2014-11-26 高连如 一种治疗2型糖尿病的基因工程干细胞
EP3822287A1 (en) * 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516518A (ja) 2011-04-25 2014-07-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 共通の軽鎖を有する抗体を発現する非ヒト動物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｐｕｒｉｆｉｅｄ ａｎｔｉ－Ｂｅｔａｔｒｏｐｈｉｎ （ＡＮＧＰＴＬ８） Ａｎｔｉｂｏｄｙ，２０１４．７．２５，ｒｅｔｒｉｅｖｅｄ ｆｒｏｍ ｔｈｅ Ｉｎｔｅｒｎｅｔ，ｒｅｔｒｉｅｖｅｄ ｏｎ ２０２０．７．１５，＜ＵＲＬ：ｈｔｔｐｓ：／／ｗｗｗ．ｂｉｏｌｅｇｅｎｄ．ｃｏｍ／ｅｎ－ｕｓ／ｇｌｏｂａｌ－ｅｌｅｍｅｎｔｓ／ｐｄｆ－ｐｏｐｕｐ／ｐｕｒｉｆｉｅｄ－ａｎｔｉ－ｂｅｔａｔｒｏｐｈｉｎ－ａｎｇｐｔｌ８－ａｎｔｉｂｏｄｙ－１０１１３＞
Ｚｈａｎｇ，Ｒ．Ａ，Ｅｎｄｏｃｒｉｎｅ Ｓｏｃｉｅｔｙ’ｓ ９７ｔｈ Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ ａｎｄ Ｅｘｐｏ，２０１５．３．８，ＯＲ１３－６

Also Published As

Publication number Publication date
CN107922478A (zh) 2018-04-17
MX2018001532A (es) 2018-03-15
KR20180038020A (ko) 2018-04-13
JP2021090449A (ja) 2021-06-17
WO2017027316A1 (en) 2017-02-16
MX394103B (es) 2025-03-24
US20170037124A1 (en) 2017-02-09
US10259870B2 (en) 2019-04-16
IL257263A (en) 2018-03-29
CA2993976A1 (en) 2017-02-16
EP3331908A1 (en) 2018-06-13
ZA201800352B (en) 2018-12-19
EP3331908B1 (en) 2021-03-10
AU2016307430B2 (en) 2022-04-21
JP2018525383A (ja) 2018-09-06
TW201713690A (zh) 2017-04-16
ES2870031T3 (es) 2021-10-26
EA201890453A1 (ru) 2018-07-31
EA035088B1 (ru) 2020-04-27
AR105600A1 (es) 2017-10-18
AU2016307430A1 (en) 2018-02-22
HK1250238A1 (zh) 2018-12-07

Similar Documents

Publication Publication Date Title
US10259870B2 (en) Anti-ANGPTL8 antibodies and uses thereof
US9657099B2 (en) Anti-glucagon antibodies
JP7133551B2 (ja) 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法
CA2818426C (en) Human antibodies to the glucagon receptor
JP7807238B2 (ja) 骨形成タンパク質６に対するヒト抗体
HK40014899A (en) Human antibodies to the glucagon receptor
HK1190159B (en) Human antibodies to the glucagon receptor
HK1190159A (en) Human antibodies to the glucagon receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210304

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220719

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220816

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220909

R150 Certificate of patent or registration of utility model

Ref document number: 7141333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150